Publications by authors named "W David Wilson"
Background: The burden of inflammatory bowel disease (IBD) is often reported on from a system or cost viewpoint. We created and explored a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort.
Aim: To create and explore a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort, and correlate PPBoD scores with demographics, disease and treatment factors.
Background: Patients with systemic right ventricle (SRV), either d-transposition of the great arteries following an atrial switch procedure or congenitally corrected transposition of the great arteries, develop severe right ventricular dysfunction, prompting appropriate medical therapy. However, the efficacy of beta-blockers and angiotensin receptor blockers or angiotensin-converting enzyme inhibitors (ACEI) in SRV patients is unproven.
Objectives: The objective of this study was to determine the effects of ACEI/ARB and beta-blockers on outcomes in SRV patients after accounting for likely cofounders affecting their use.
Arthropod-borne members of the genus cause significant human disease. Four serotypes of dengue virus are endemic globally, and approximately 50 percent of the world's population lives in a dengue-affected area. Complications from immunoenhancement occurring after a secondary infection with a different dengue serotype make vaccine development challenging.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the long-term effects of afatinib in patients with EGFR mutant non-small cell lung cancer (NSCLC) who also had other health issues, and assessed the usefulness of monitoring circulating tumor DNA (ctDNA).
- Conducted in the UK, the TIMELY trial involved patients receiving afatinib daily until their disease progressed or they experienced significant side effects, with blood samples analyzed every 12 weeks.
- Results showed that while the median progression-free survival was 7.9 months, some patients experienced long-term benefits, and ctDNA testing improved the detection of EGFR mutations and was linked to better outcomes.